Partial
Not Aligned
Patient Risk:
Moderate
Summary
Several claims match the provided label excerpts (indications, contraindication for hypersensitivity, increased bleeding with concomitant antithrombotics, monitoring for bleeding with anticoagulants/antiplatelets). However, multiple contraindication/safety assertions are contradicted or not supported by the supplied label text (pancreatitis contraindication, anticoagulant contraindication, specific phrasing of pancreatitis risk, and pregnancy/breastfeeding and pediatric “not recommended” statements). Key dosing/administration and monitoring items are also partially inaccurate or missing relative to label guidance.
Category Scores
Accurate Statements
Vascepa is used to reduce the risk of cardiovascular events in adults with established cardiovascular disease.
Label indication for reducing risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adults with elevated TG and established cardiovascular disease.
Vascepa is contraindicated in patients with severe hypersensitivity reactions to icosapent ethyl or any inactive ingredients.
CONTRAINDICATIONS: "contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components."
Vascepa may increase the risk of bleeding.
WARNINGS/ PRECAUTIONS (Bleeding): "VASCEPA is associated with an increased risk of bleeding."
The increased risk of bleeding with Vascepa is particularly relevant in patients taking anticoagulants or antiplatelet agents.
Bleeding: "The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin."
Vascepa may increase the risk of bleeding when taken with anticoagulants such as warfarin.
Bleeding: bleeding incidence greater with concomitant antithrombotic medications including "warfarin".
Vascepa may increase the risk of bleeding when taken with antiplatelet agents such as aspirin.
Bleeding: bleeding incidence greater with concomitant antithrombotic medications including "aspirin".
Vascepa may decrease the absorption of cholestyramine.
Patients taking Vascepa should be monitored for signs of bleeding such as bruising or bleeding gums.
DRUG INTERACTIONS 7.1: "Monitor patients receiving VASCEPA and concomitant anticoagulants and/or antiplatelet agents for bleeding." (Specific example terms like bruising/bleeding gums are not in provided excerpts.)
Unsupported Statements
Vascepa (icosapent ethyl) is a prescription medication used to lower triglyceride levels in adults with severe hypertriglyceridemia.
Label supports adjunct to diet to reduce TG levels in adults with severe (≥500 mg/dL) hypertriglyceridemia, but the supplied excerpts also indicate another cardiovascular-risk indication; this statement is generally consistent yet not fully specific to the label wording that it is an adjunct to diet and specifies the TG definition (though TG definition is included in the excerpts).
Vascepa is contraindicated in patients with a history of pancreatitis.
The provided label excerpt does not list pancreatitis as a contraindication.
Vascepa is contraindicated in patients with concomitant use of anticoagulants.
The provided label excerpt describes increased bleeding risk and monitoring with concomitant anticoagulants/antiplatelet agents, not contraindication.
Vascepa is contraindicated in patients taking anticoagulants such as warfarin because it may increase the risk of bleeding.
Provided excerpts do not state a contraindication for anticoagulants; they discuss increased bleeding incidence and monitoring.
The increased risk of bleeding with Vascepa is particularly relevant in patients taking anticoagulants or antiplatelet agents.
Overall concept is supported, but phrasing that it is 'particularly relevant' for anticoagulants/antiplatelets is an interpretive emphasis beyond the provided sentence; however the underlying claim about greater bleeding incidence with concomitant antithrombotics is supported.
Vascepa may increase the risk of pancreatitis.
Provided label states: "Limitations of Use: The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined." This does not support a claim that it may increase risk.
The increased risk of pancreatitis with Vascepa is particularly relevant in patients with a history of pancreatitis.
No provided label support for increased pancreatitis risk, nor for higher relevance in patients with a history of pancreatitis.
Vascepa may increase the risk of cardiovascular events such as heart attack, stroke, or death.
The provided label excerpts describe reduction in risk of specific cardiovascular events; they do not support increased risk.
The increased risk of cardiovascular events with Vascepa is particularly relevant in patients with established cardiovascular disease.
No support for increased cardiovascular risk; indication excerpt states risk reduction.
Vascepa may decrease the absorption of cholestyramine.
No cholestyramine interaction is included in the provided excerpts.
Vascepa is not recommended for use in pregnant or breastfeeding women.
Provided label excerpts indicate insufficient pregnancy data to identify risk; they do not state 'not recommended'. For lactation, label provides detection in milk and lack of data on infant/milk production; it does not state 'not recommended'.
Vascepa is not recommended for use in pregnant or breastfeeding women because its effects on the fetus or infant are unknown.
Excerpts do not use the term 'not recommended' and provide a different framing (insufficient data). This is not directly supported as stated.
Vascepa is not recommended for use in children and adolescents.
No pediatric language is present in the provided label excerpts; the statement is unsupported by supplied text.
The safety and efficacy of Vascepa have not been established in children and adolescents.
No pediatric section/excerpt is provided to support this statement.
Patients taking Vascepa should have triglyceride levels checked regularly.
Provided excerpts instruct to assess lipid levels before initiation, but do not specify regular monitoring frequency during therapy.
Patients taking Vascepa should have liver function tests checked regularly.
Provided excerpt: "In patients with hepatic impairment... ALT and AST levels should be monitored periodically." This does not support 'for patients' generally nor specify routine regular monitoring for all patients.
Vascepa may cause abdominal pain.
No 'abdominal pain' adverse reaction excerpt is included. Provided adverse reactions include musculoskeletal pain, peripheral edema, constipation, gout, atrial fibrillation, and in another pooled analysis arthralgia and oropharyngeal pain.
Abdominal pain with Vascepa may be particularly relevant in patients with a history of pancreatitis.
No abdominal pain adverse reaction support, and no provided label linkage to history of pancreatitis.
Vascepa may cause nausea and vomiting.
No nausea/vomiting adverse reaction excerpt is included.
Nausea and vomiting with Vascepa may be particularly relevant in patients with a history of gastrointestinal disorders.
No nausea/vomiting support, nor any provided label linkage to GI disorder history.
Vascepa may cause diarrhea.
No diarrhea adverse reaction excerpt is included.
Diarrhea with Vascepa may be particularly relevant in patients with a history of gastrointestinal disorders.
No diarrhea support, nor any provided label linkage to GI disorder history.
Contradictions
High
AI Statement
Vascepa is contraindicated in patients with a history of pancreatitis.
Label Reference
Provided label only states: "Limitations of Use: The effect of VASCEPA on the risk for pancreatitis... has not been determined." It does not list pancreatitis history as a contraindication.
High
AI Statement
Vascepa is contraindicated in patients with concomitant use of anticoagulants.
Label Reference
WARNINGS/PRECAUTIONS Bleeding and DRUG INTERACTIONS 7.1 describe increased bleeding risk and monitoring with concomitant anticoagulants/antiplatelet agents; no contraindication is provided in the excerpts.
High
AI Statement
Vascepa may increase the risk of pancreatitis.
Label Reference
Limitations of Use: "The effect of VASCEPA on the risk for pancreatitis... has not been determined."
High
AI Statement
Vascepa may increase the risk of cardiovascular events such as heart attack, stroke, or death.
Label Reference
INDICATIONS: adjunct to maximally tolerated statin therapy "to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization".
Important Omissions
Correct dosing instructions are not provided (label: 4 g/day as either four 0.5 g capsules twice daily with food, or two 1 g capsules twice daily with food; swallow whole; do not break/crush/chew).
Importance:
High
The label limitation regarding pancreatitis risk (effect not determined) is omitted or contradicted by the AI claims.
Importance:
High
Atrial fibrillation/flutter risk is not mentioned although present in the provided warnings excerpt.
Importance:
Moderate
Specific administration instructions (swallow whole; with food) are omitted.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple statements conflict with label excerpts (cardiovascular events described as increased risk; pancreatitis risk described as increased; anticoagulant use stated as contraindicated). These could lead to incorrect patient selection or misunderstanding of benefits/risks. Other unsupported claims (e.g., GI adverse reactions) may misinform risk counseling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Several safety/contraindication and risk assertions directly contradict the supplied VASCEPA label excerpts (pancreatitis risk and cardiovascular event risk; anticoagulant contraindication; pancreatitis history contraindication).
Suggested Improvement
Replace contradicted claims with on-label language: contraindications limited to known hypersensitivity to VASCEPA/components; acknowledge bleeding risk is increased with concomitant antithrombotics and requires monitoring; state pancreatitis risk effect is not determined (limitations of use); frame cardiovascular outcomes per indication as risk reduction; only include adverse reactions and interactions that are present in the provided label excerpts. Include label dosing/administration instructions (4 g/day with food; swallow whole; do not crush/break/open).